Patient characteristics, source of progenitor cells, and GVHD prophylaxis (n = 44)
| Patient no. . | Age . | Sex . | Disease . | Previous failed transplant/prior lines of therapy . | Previous radiotherapy . | Status at transplantation . | Source of donor cells . | CD34+ × 106/kg (PBSC) MNC × 108/kg (marrow) . | GVHD prophylaxis . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 53 | M | MCL | No/3 | No | CR-1 | PBSC/sibling | 6.1 | CsA + MTX |
| 2 | 27 | M | HD | No/3 | Local | CR-2 | PBSC/sibling | 3.2 | CsA + MTX |
| 3 | 32 | M | AML | No/3 | Local | CR-3 | PBSC/sibling | 6.6 | CsA + MTX |
| 4 | 54 | M | LG-NHL-T | Auto/5 | Local + TBI | PR | PBSC/sibling | 3.1 | CsA + MTX |
| 5 | 25 | F | HD | Auto/5 | Local | PR | PBSC/sibling | 4.6 | CsA |
| 6 | 41 | M | HD | Auto/6 | Local × 2 | PR | PBSC/sibling | 4.1 | CsA |
| 7 | 41 | M | LG-NHL | No/3 | No | CR-1 | PBSC/sibling | 4.6 | CsA |
| 8 | 45 | M | MDS | Auto/4 | Local | PR | Marrow/MUD | 2.64 | CsA |
| 9 | 38 | M | HG-NHL | Auto/3 | Local | PR | Marrow/MUD | 3.52 | CsA |
| 10 | 48 | F | MM | Auto/2 | No | PR | PBSC/sibling | 4.22 | CsA + MTX |
| 11 | 44 | M | MM | Allo/2 | No | PR | PBSC/sibling | 3.87 | CsA + MTX |
| 12 | 42 | F | AML | No/2 | No | Refractory | PBSC/sibling | 5.9 | CsA |
| 13 | 51 | F | AML | No/2 | No | Refractory | PBSC/sibling | 1 + 6 | CsA |
| 14 | 25 | M | HD | Auto/4 | Local | CR-4 | PBSC/sibling | 6.4 | CsA |
| 15 | 35 | M | LG-NHL | Auto/4 | No | PR | PBSC/sibling | 5.6 | CsA |
| 16 | 18 | M | ALL | Auto/3 | TBI | CR-2 | Marrow/MUD | 4.3 | CsA |
| 17 | 32 | F | HD | Auto/4 | No | Refractory | PBSC/sibling | 5.7 | CsA |
| 18 | 39 | M | HD | Auto/4 | Local | PR | PBSC/sibling | 12.2 | CsA |
| 19 | 30 | M | AML | Auto/3 | TBI | CR-2 | Marrow/MUD | 6.9 | CsA |
| 20 | 35 | F | HD | No/4 | Local | Refractory | PBSC/sibling | 6.9 | CsA |
| 21 | 50 | M | LG-NHL | No/2 | Local | CR-2 | PBSC/sibling | 3.19 | CsA |
| 22 | 48 | M | LG-NHL-T | No/4 | No | Refractory | PBSC/sibling | 6.73 | CsA |
| 23 | 40 | F | MM | No/2 | No | PR | PBSC/sibling | 3.9 | CsA |
| 24 | 49 | F | MDS | No/0 | No | PR | PBSC/sibling | 9.3 | CsA |
| 25 | 38 | F | LG-NHL-T | No/5 | No | Refractory | PBSC/sibling | 7.5 | CsA |
| 26 | 44 | F | AML | Auto/3 | TBI | CR-2 | Marrow/MUD | 2.9 | CsA |
| 27 | 33 | F | HD | No/3 | Local | CR-3 | PBSC/sibling | 4.17 | CsA |
| 28 | 43 | F | MM | No/1 | No | PR | PBSC/sibling | 21.1 | CsA |
| 29 | 50 | M | MCL | No/1 | No | CR-1 | PBSC/sibling | 9.25 | CsA |
| 30 | 50 | M | AML | No/2 | No | CR-2 | PBSC/sibling | 2.28 | CsA |
| 31 | 20 | M | HG-NHL | No/4 | Local | Refractory | PBSC/sibling | 2.98 | CsA |
| 32 | 49 | M | MM | Auto/3 | Local | PR | PBSC/sibling | 5.1 | CsA |
| 33 | 49 | M | MDS | No/0 | No | PR | PBSC/sibling | 0.55 + 0.65 | CsA |
| 34 | 43 | M | LG-NHL | No/4 | No | CR-2 | PBSC/sibling | 8.9 | CsA |
| 35 | 56 | M | LG-NHL-T | No/4 | Local | Refractory | PBSC/sibling | 2.1 | CsA |
| 36 | 31 | M | HD | Auto/4 | No | CR-3 | PBSC/sibling | 2.95 | CsA |
| 37 | 44 | M | MCL | Auto/3 | No | CR-3 | PBSC/sibling | 5.29 | CsA |
| 38 | 37 | M | CLL | No/2 | No | PR | PBSC/sibling | 4.4 | CsA |
| 39 | 37 | M | LG-NHL | No/5 | No | PR | PBSC/sibling | 3.5 | CsA |
| 40 | 22 | F | HD | Auto/4 | No | PR | Marrow/MUD | 4.79 | CsA |
| 41 | 35 | M | PCL | No/1 | No | CR-1 | Marrow/MUD | 2.29 | CsA |
| 42 | 46 | F | MM | No/1 | No | PR | PBSC/sibling | 6.8 | CsA |
| 43 | 48 | F | MM | Auto/5 | Local | Refractory | PBSC/sibling | 5.94 | CsA |
| 44 | 53 | F | CML | No/1 | No | CP-1 | Marrow/MUD | 2.6 | CsA |
| Patient no. . | Age . | Sex . | Disease . | Previous failed transplant/prior lines of therapy . | Previous radiotherapy . | Status at transplantation . | Source of donor cells . | CD34+ × 106/kg (PBSC) MNC × 108/kg (marrow) . | GVHD prophylaxis . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 53 | M | MCL | No/3 | No | CR-1 | PBSC/sibling | 6.1 | CsA + MTX |
| 2 | 27 | M | HD | No/3 | Local | CR-2 | PBSC/sibling | 3.2 | CsA + MTX |
| 3 | 32 | M | AML | No/3 | Local | CR-3 | PBSC/sibling | 6.6 | CsA + MTX |
| 4 | 54 | M | LG-NHL-T | Auto/5 | Local + TBI | PR | PBSC/sibling | 3.1 | CsA + MTX |
| 5 | 25 | F | HD | Auto/5 | Local | PR | PBSC/sibling | 4.6 | CsA |
| 6 | 41 | M | HD | Auto/6 | Local × 2 | PR | PBSC/sibling | 4.1 | CsA |
| 7 | 41 | M | LG-NHL | No/3 | No | CR-1 | PBSC/sibling | 4.6 | CsA |
| 8 | 45 | M | MDS | Auto/4 | Local | PR | Marrow/MUD | 2.64 | CsA |
| 9 | 38 | M | HG-NHL | Auto/3 | Local | PR | Marrow/MUD | 3.52 | CsA |
| 10 | 48 | F | MM | Auto/2 | No | PR | PBSC/sibling | 4.22 | CsA + MTX |
| 11 | 44 | M | MM | Allo/2 | No | PR | PBSC/sibling | 3.87 | CsA + MTX |
| 12 | 42 | F | AML | No/2 | No | Refractory | PBSC/sibling | 5.9 | CsA |
| 13 | 51 | F | AML | No/2 | No | Refractory | PBSC/sibling | 1 + 6 | CsA |
| 14 | 25 | M | HD | Auto/4 | Local | CR-4 | PBSC/sibling | 6.4 | CsA |
| 15 | 35 | M | LG-NHL | Auto/4 | No | PR | PBSC/sibling | 5.6 | CsA |
| 16 | 18 | M | ALL | Auto/3 | TBI | CR-2 | Marrow/MUD | 4.3 | CsA |
| 17 | 32 | F | HD | Auto/4 | No | Refractory | PBSC/sibling | 5.7 | CsA |
| 18 | 39 | M | HD | Auto/4 | Local | PR | PBSC/sibling | 12.2 | CsA |
| 19 | 30 | M | AML | Auto/3 | TBI | CR-2 | Marrow/MUD | 6.9 | CsA |
| 20 | 35 | F | HD | No/4 | Local | Refractory | PBSC/sibling | 6.9 | CsA |
| 21 | 50 | M | LG-NHL | No/2 | Local | CR-2 | PBSC/sibling | 3.19 | CsA |
| 22 | 48 | M | LG-NHL-T | No/4 | No | Refractory | PBSC/sibling | 6.73 | CsA |
| 23 | 40 | F | MM | No/2 | No | PR | PBSC/sibling | 3.9 | CsA |
| 24 | 49 | F | MDS | No/0 | No | PR | PBSC/sibling | 9.3 | CsA |
| 25 | 38 | F | LG-NHL-T | No/5 | No | Refractory | PBSC/sibling | 7.5 | CsA |
| 26 | 44 | F | AML | Auto/3 | TBI | CR-2 | Marrow/MUD | 2.9 | CsA |
| 27 | 33 | F | HD | No/3 | Local | CR-3 | PBSC/sibling | 4.17 | CsA |
| 28 | 43 | F | MM | No/1 | No | PR | PBSC/sibling | 21.1 | CsA |
| 29 | 50 | M | MCL | No/1 | No | CR-1 | PBSC/sibling | 9.25 | CsA |
| 30 | 50 | M | AML | No/2 | No | CR-2 | PBSC/sibling | 2.28 | CsA |
| 31 | 20 | M | HG-NHL | No/4 | Local | Refractory | PBSC/sibling | 2.98 | CsA |
| 32 | 49 | M | MM | Auto/3 | Local | PR | PBSC/sibling | 5.1 | CsA |
| 33 | 49 | M | MDS | No/0 | No | PR | PBSC/sibling | 0.55 + 0.65 | CsA |
| 34 | 43 | M | LG-NHL | No/4 | No | CR-2 | PBSC/sibling | 8.9 | CsA |
| 35 | 56 | M | LG-NHL-T | No/4 | Local | Refractory | PBSC/sibling | 2.1 | CsA |
| 36 | 31 | M | HD | Auto/4 | No | CR-3 | PBSC/sibling | 2.95 | CsA |
| 37 | 44 | M | MCL | Auto/3 | No | CR-3 | PBSC/sibling | 5.29 | CsA |
| 38 | 37 | M | CLL | No/2 | No | PR | PBSC/sibling | 4.4 | CsA |
| 39 | 37 | M | LG-NHL | No/5 | No | PR | PBSC/sibling | 3.5 | CsA |
| 40 | 22 | F | HD | Auto/4 | No | PR | Marrow/MUD | 4.79 | CsA |
| 41 | 35 | M | PCL | No/1 | No | CR-1 | Marrow/MUD | 2.29 | CsA |
| 42 | 46 | F | MM | No/1 | No | PR | PBSC/sibling | 6.8 | CsA |
| 43 | 48 | F | MM | Auto/5 | Local | Refractory | PBSC/sibling | 5.94 | CsA |
| 44 | 53 | F | CML | No/1 | No | CP-1 | Marrow/MUD | 2.6 | CsA |
MCL indicates mantle cell lymphoma; HD, Hodgkin disease; AML, acute myeloid leukemia; LG-NHL, low-grade non-Hodgkin lymphoma; T, transformed low-grade to high-grade lymphoma; MDS, myelodysplastic syndrome; HG-NHL, high-grade non-Hodgkin lymphoma; MM, multiple myeloma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR, complete remission; PR, partial remission; CP, chronic phase; PBSC, peripheral blood stem cells; MUD, matched unrelated donor; CsA, cyclosporine A; MTX, methotrexate; TBI, total body irradiation.